BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Torres-Benito L, Schneider S, Rombo R, Ling KK, Grysko V, Upadhyay A, Kononenko NL, Rigo F, Bennett CF, Wirth B. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice. Am J Hum Genet 2019;105:221-30. [PMID: 31230718 DOI: 10.1016/j.ajhg.2019.05.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhuri D, Gurkan H, Eker D, Karal Y, Yalcintepe S, Atli E, Demir S, Atli EI. Investigation on the Effects of Modifying Genes on the Spinal Muscular Atrophy Phenotype. Glob Med Genet 2022;09:226-236. [DOI: 10.1055/s-0042-1751302] [Reference Citation Analysis]
2 Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers 2022;8:52. [PMID: 35927425 DOI: 10.1038/s41572-022-00380-8] [Reference Citation Analysis]
3 Muinos-Bühl A, Rombo R, Janzen E, Ling KK, Hupperich K, Rigo F, Bennett CF, Wirth B. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks. Neurobiol Dis 2022;171:105795. [PMID: 35724821 DOI: 10.1016/j.nbd.2022.105795] [Reference Citation Analysis]
4 Maretina MA, Kiselev AV, Ilina AV, Egorova AA, Glotov AS, Bespalova ON, Baranov VS, Kogan IY. Current Trends in the Diagnosis, Screening and Treatment of Spinal Muscular Atrophy. Annals RAMS 2022;77:87-96. [DOI: 10.15690/vramn1768] [Reference Citation Analysis]
5 Oberemok VV, Andreeva OA, Laikova KV, Novikov IA, Kubyshkin AV. Post-genomic platform for development of oligonucleotide vaccines against RNA viruses: diamond cuts diamond. Inflamm Res 2022. [PMID: 35523969 DOI: 10.1007/s00011-022-01582-2] [Reference Citation Analysis]
6 Jablonka S, Hennlein L, Sendtner M. Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders. Neurol Res Pract 2022;4:2. [PMID: 34983696 DOI: 10.1186/s42466-021-00162-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Chaytow H, Faller KME, Huang YT, Gillingwater TH. Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine. Cell Rep Med 2021;2:100346. [PMID: 34337562 DOI: 10.1016/j.xcrm.2021.100346] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 20.0] [Reference Citation Analysis]
8 Servais L, Baranello G, Scoto M, Daron A, Oskoui M. Therapeutic interventions for spinal muscular atrophy: preclinical and early clinical development opportunities. Expert Opin Investig Drugs 2021;30:519-27. [PMID: 33749510 DOI: 10.1080/13543784.2021.1904889] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
9 Zhang YX, Zhang XT, Li HJ, Zhou TF, Zhou AC, Zhong ZL, Liu YH, Yuan LL, Zhu HY, Luan D, Tong JC. Antidepressant-like effects of helicid on a chronic unpredictable mild stress-induced depression rat model: Inhibiting the IKK/IκBα/NF-κB pathway through NCALD to reduce inflammation. Int Immunopharmacol 2021;93:107165. [PMID: 33578182 DOI: 10.1016/j.intimp.2020.107165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
10 Ojala KS, Reedich EJ, DiDonato CJ, Meriney SD. In Search of a Cure: The Development of Therapeutics to Alter the Progression of Spinal Muscular Atrophy. Brain Sci 2021;11:194. [PMID: 33562482 DOI: 10.3390/brainsci11020194] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
11 Wirth B. Spinal Muscular Atrophy: In the Challenge Lies a Solution. Trends Neurosci 2021;44:306-22. [PMID: 33423791 DOI: 10.1016/j.tins.2020.11.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 40.0] [Reference Citation Analysis]
12 Rouzier C, Chaussenot A, Paquis-flucklinger V. Molecular diagnosis and genetic counseling for spinal muscular atrophy (SMA). Archives de Pédiatrie 2020;27:7S9-7S14. [DOI: 10.1016/s0929-693x(20)30270-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Kaifer KA, Villalón E, Smith CE, Simon ME, Marquez J, Hopkins AE, Morcos TI, Lorson CL. AAV9-DOK7 gene therapy reduces disease severity in Smn2B/- SMA model mice. Biochem Biophys Res Commun 2020;530:107-14. [PMID: 32828271 DOI: 10.1016/j.bbrc.2020.07.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
14 Smeriglio P, Langard P, Querin G, Biferi MG. The Identification of Novel Biomarkers Is Required to Improve Adult SMA Patient Stratification, Diagnosis and Treatment. J Pers Med 2020;10:E75. [PMID: 32751151 DOI: 10.3390/jpm10030075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
15 Feng LY, Li L. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer. J Ovarian Res 2020;13:35. [PMID: 32228639 DOI: 10.1186/s13048-020-00635-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]